RxDoctor Payments Data

Mahdi Veillet-Chowdhury, MD

Cardiovascular Disease · Honolulu, HINPI 1174781678

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,438 of the $6,990 with a category attached, or 92.1%. 7 manufacturers reported payments, led by Boston Scientific at 57.3% of the total. Reporting peaked in 2021 at $6,459 and has fallen 92.9% since, to $461 in 2024.

$6,990in general payments, 2019–2025

Across 9 payments — averaging $776.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Canon Medical Systems USA, Inc.$3K
  • Heartflow, Inc.$166
  • Shockwave Medical, Inc$158
  • E.r. Squibb & Sons, L.L.C.$122
  • Boehringer Ingelheim$21
  • plus $15 from 1 others

What the payments were for

  • Consulting fees$6,43892%
  • Food & beverage$5528%

General payments by program year

19
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,990 in reported general payments places this provider in the 75th percentile of 73 cardiovascular disease providers in Hawaii.

See all cardiovascular disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$209,950
Medicare patients
1,080
Services billed
2,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$362,246
XareltoRivaroxaban54$79,542
EntrestoSacubitril/Valsartan36$39,026
BrilintaTicagrelor36$34,776
JardianceEmpagliflozin19$32,975
Repatha SureclickEvolocumab36$30,366
VascepaIcosapent Ethyl17$14,007
Atorvastatin Calcium378$10,249
Metoprolol Succinate377$5,507
Amlodipine Besylate285$3,373
Ezetimibe64$2,649
Rosuvastatin Calcium64$2,321
Losartan Potassium105$1,583
Carvedilol135$1,418
ClopidogrelClopidogrel Bisulfate40$1,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$32,97519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 73 cardiovascular disease providers in Hawaii.

Other cardiovascular disease in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →